@ http://investorshub.advfn.com/Best-of-iHub-29918/
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We recently announced the coming launch of a sister network, EFN, The Erotic Film Network, which will contain the largest library of erotic films in the world. No one else has that programming mix.
Having acquired over 5000 titles, we are continuing an aggressive acquisition model with a broad mix of horror, cult classics, sci-fi, vintage TV and numerous other genres.
HBO and CBS are the first major players to announce an internet subscription model, allowing the consumer the option to bypass the cable box, often referred to as "cutting the cord."
"The key is that internet content delivery has now been completely legitimized. Millions of consumers worldwide now have a growing variety of VOD options. Historically, the entertainment industry has bred independent companies that succeed right along with the majors.
Huge REVS are gonna come into this ticker!!! :D
"We saw a sea change in how media was being consumed, which is why we got in early. This has been our model for the past two years." Industry veteran Greenwald knows content and distribution, having founded and run Image Entertainment, building it into a powerhouse with over $100 Million in annual revenue and over 14,000 titles in its library.
This week's back-to-back announcements of HBO and CBS entering the internet subscription market are a welcome boon to The Digital Development Group's flagship brand, The Movie & Music Network, says the CEO.
L2 super thin!!! Its just a matter of time this explodes! ^^
>>>>>MULTIBAGGER $DIDG<<<<<<<<
Close with green plus HUGE VOLUME!!! :D
Loaded few yesterday!!! Gonna load up more!
Volume has been awesome with huge accumulation!!! :D
Wow. Thats great info!! :D
Been keeping an eye on this one for quite a while! Charts never lie and it looks promising :D
The two companies have been collaborating on the design of Verde Science's research and development plan and protocols and have agreed on principles of a long-term association.
Following basic research Verde expects to develop a point-of-care testing kit that will enable health care practitioners to effectively screen for Ebola sometime in 2015.
Verde Science, Inc., a Medical Research and Development Company focused on effective treatments for emerging and contemporary health issues, is pleased to announce that it has executed a definitive pharmaceutical development agreement with Sterkem Group (www.sterkempharma.com) a Mumbai, India based pharmaceutical firm.
Richmond, BC / ACCESSWIRE / November 10, 2014 / Verde Science, Inc., (VRCI) a Medical Research and Development Company focused on novel effective treatments for emerging and contemporary health issues, is pleased to announce that it is working with three new members of its R&D team in Canada and India to develop an easily administered point-of-care test for screening for Ebola and other closely related viruses.
that is one sexy news!! :) love it!@
VRCI running baby!! :D
gonna load this cheapies! ^^ When the news hit, we all know this is going 0.3-0.5! ^^
“This approach along with our synergistic and highly skilled team will streamline our processes and yield optimal results, without having to wait for a R&D license in Canada”, concluded Mr. Patel.
“We are immediately beginning the coordinated design of our overall R&D program with our front end and back end team members in India, so that all members of the team will be constantly in the feedback loop throughout the R&D process for each compound we are studying”, according to Manit Patel.
Sterkem Group – Verde Science and Sterkem Group (www.sterkempharma.com) a Mumbai, India based pharmaceutical research, production and marketing firm, are finalizing the plan for a pharmaceutical development venture that will refine the resultant cannabis-based extracts for specific medical conditions identified by Verde’s R&D program into deliverable and marketable pharmaceutical formulations.
The Institute of Chemical Technology – The ICT and Verde Science are moving toward an alliance that will offer expanded research capabilities for Verde’s ongoing scientific inquiries that will utilize faculty and graduate students to supplement Verde’s internal scientists.
Both researchers are faculty at the Institute of Chemical Technology and will be pivotal to cost effective extraction, isolation and formulation design from the marijuana plant.
Drs. Ratnesh Jain and Prajatka Dandekar Jain, Senior Researchers – Dr. Prajakta Jain has a Ph.D. in Bioprocess Technology with expertise in extraction and isolation of active ingredients from plants. Dr. Ratnesh Jain has a Ph.D. in nanocarriers and drug delivery systems.
Expertise in pharmaceutical research, product design, production, and business strategy and development, with a broad network of international business contacts. He has successfully launched 9 products for Sterkem during his tenure.
Manit Patel, CTO -- B.Sc. in Pharmaceutical Science from the Institute of Chemical Technology of Mumbai, India. MBA from Queensland University of Technology in Brisbane, Australia.
Richmond, BC - November 04, 2014 - (OTCPK: VRCI) Verde Science, Inc., a Medical Research and Development Company, is pleased to announce that it has assembled its complete Research and Development team under the direction of its newly appointed Chief Technology Officer, Manit Patel, and it has initiated the coordinated design of its overarching R&D plan. The recently completed team includes:
The principals and researchers of Sterkem possess an array of experience and skills that compliment Verde’s staff, and enable us to rapidly move forward on our R&D efforts without the time and expense of building our own back end team.”
Harp Sangha, Verde’s CEO, explained “I am pleased to formally add Sterkem Group to our research group. The Sterkem team is well known to us, since we have been working closely for a long time.
The companies will share revenues from the sale of products and licensing fees.
Under the terms of the agreement, Sterkem Group will help refine the cannabis-based extracts identified by Verde Science’s research and development efforts as effective for the treatment of specific medical conditions, into deliverable and marketable pharmaceutical formulations.
The two companies have been collaborating on the design of Verde Science’s research and development plan and protocols and have agreed on principles of a long-term association.
Surrey, BC - November 06, 2014 - InvestorsHub NewsWire - (OTCPK: VRCI) Verde Science, Inc., a Medical Research and Development Company focused on effective treatments for emerging and contemporary health issues, is pleased to announce that it has executed a definitive pharmaceutical development agreement with Sterkem Group (www.sterkempharma.com) a Mumbai, India based pharmaceutical firm.
$VRCI is gonna run hard.
heard huge news gonna hit this soon! :)
dip and run!! this is how SIPC trades... :D i am loaded..how about you? :D
This baby getting ready for huge run!!! GO SIPC!!!
Charts look so pretty!!!! :)